GlassScriptPhysician profile
Kelly Barham
NPI 1447454160
$1,002.49
in general payments reported to CMS, 2019-2025
14 companies · $65.85 in 2025
The $65.85 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $79.23 · 2021: $79.86 · 2022: $120 · 2023: $221 · 2024: $128 · 2025: $65.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $399.71 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $336.39 | 2019-2022 | |
| Abbvie INC. | $238.90 | 2019-2024 | Botox |
| Ucb, INC. | $64.19 | 2023 | Cimzia, Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $57.19 | 2020 | |
| Pfizer INC. | $57.15 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $53.96 | 2024-2025 | |
| Galderma Laboratories, L.P. | $39.21 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $38.50 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.25 | 2019 | |
| Leo Pharma INC. | $18.66 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.17 | 2022 | |
| Botanix Sb INC | $17.02 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $16.81 | 2024 | Daxxify |
| Almirall LLC | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Barham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.